Reference and retention samples (clause 6.14) for medicinal gases are not required, as outlined in Annex 6 clause 43, and therefore compliance with this clause is not expected.
Method validation (clause 6.15) is not normally required where official test methods outlined within the default standards, (BP, Ph. Eur. or USP) are adhered to.
Ongoing stability programmes (clauses 6.26 - 6.36) for medicinal gases are not generally required, as outlined in Annex 6 clause 44. If stability requirements are detailed in the market authorisation of a product, then ongoing stability testing may be necessary.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.